Crinetics Pharmaceuticals Announced Topline Results From Phase 2 Study Of Atumelnant For Classic Congenital Adrenal Hyperplasia And Adrenocorticotropic Hormone-dependent Cushing's Syndrome

Benzinga · 01/10 12:19
  • Substantial, Rapid and Sustained Statistically Significant Reductions of Key Biomarkers Achieved Across Doses, Including up to 80% Mean Reduction of Androstenedione
  • Meaningful Improvements Demonstrated in Multiple Clinical Signs and Symptoms of CAH Affecting Patient Health
  • Safety and Efficacy Data Support Initiation of Phase 3 Clinical Trial